Zobrazeno 1 - 10
of 552
pro vyhledávání: '"leukemia stem cell"'
Autor:
Yuan-dong Feng, Jin Du, Hong-li Chen, Ying Shen, Ya-chun Jia, Peng-yu Zhang, Aili He, Yun Yang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-21 (2024)
Abstract Hematological malignancies are a group of cancers that affect the blood, bone marrow, and lymphatic system. Cancer stem cells (CSCs) are believed to be responsible for the initiation, progression, and relapse of hematological malignancies. H
Externí odkaz:
https://doaj.org/article/bcbb4d6be6b4452a8630a120c7823fcf
Autor:
Huan Li, Zhijie Cao, Yiming Liu, Zhenya Xue, Yishuang Li, Haiyan Xing, Yingxi Xu, Runxia Gu, Shaowei Qiu, Hui Wei, Min Wang, Qing Rao, Jianxiang Wang
Publikováno v:
Molecular Oncology, Vol 18, Iss 10, Pp 2554-2568 (2024)
Persistence of quiescent leukemia stem cells (LSCs) after treatment most likely contributes to chemotherapy resistance and poor prognosis of leukemia patients. Identification of this quiescent cell population would facilitate eradicating LSCs. Here,
Externí odkaz:
https://doaj.org/article/02a4fc700d8748e999d62317f088c4b8
Autor:
Jianbiao Zhou, Wee-Joo Chng
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Acute myeloid leukemia (AML) is a complex and heterogeneous group of aggressive hematopoietic stem cell disease. The presence of diverse and functionally distinct populations of leukemia cells within the same patient’s bone marrow or blood poses a
Externí odkaz:
https://doaj.org/article/4195a1ce02d74646bf74c4d7f0641781
Autor:
Yongping Zhang, Shuting Jiang, Fuhong He, Yuanyuan Tian, Haiyang Hu, Li Gao, Lin Zhang, Aili Chen, Yixin Hu, Liyan Fan, Chun Yang, Bi Zhou, Dan Liu, Zihan Zhou, Yanxun Su, Lei Qin, Yi Wang, Hailong He, Jun Lu, Peifang Xiao, Shaoyan Hu, Qian-Fei Wang
Publikováno v:
Genome Biology, Vol 24, Iss 1, Pp 1-41 (2023)
Abstract Background Cancer patients can achieve dramatic responses to chemotherapy yet retain resistant tumor cells, which ultimately results in relapse. Although xenograft model studies have identified several cellular and molecular features that ar
Externí odkaz:
https://doaj.org/article/d1bd4f4676fc4a4c98403038f042788e
Autor:
Zhengwei Wu, Jiawang Ou, Nannan Liu, Zhixiang Wang, Junjie Chen, Zihong Cai, Xiaoli Liu, Xiao Yu, Min Dai, Hongsheng Zhou
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8956-8969 (2023)
Abstract Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy originated from leukemia stem cells (LSC). Emerging evidence suggests T‐cell immunoglobulin mucin‐3(Tim3) as surface marker for LSC. However, the clinical significa
Externí odkaz:
https://doaj.org/article/d5dfee65a4524f45ba2bc575b91889c3
Autor:
Wenqi Wu, Zeyan Shi, Zhongyuan Tang, Huiqun Li, Xiaoke Huang, Xiaolin Liang, Jing Li, Yibin Yao, Weihua Zhao, Meiqing Wu, Jun Luo, Zhenfang Liu
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-16 (2023)
Abstract Normal karyotype acute myeloid leukemia (NK-AML) is a heterogeneous hematological malignancy that contains a minor population of self-renewing leukemia stem cells (LSCs), which complicate efforts to achieve long-term survival. We performed s
Externí odkaz:
https://doaj.org/article/ed386b3963bd4341bef93eade0934ebe
Autor:
Qiang Qiu, Linyu yang, Yunyu Feng, Zejiang Zhu, Ning Li, Li Zheng, Yuanyuan Sun, Cong Pan, Huandi Qiu, Xue Cui, Wei He, Fang Wang, Yuyao Yi, Minghai Tang, Zhuang Yang, Yunfan Yang, Zhihui Li, Lijuan Chen, Yiguo Hu
Publikováno v:
Bioactive Materials, Vol 21, Iss , Pp 483-498 (2023)
Purinostat Mesylate (PM) is a novel highly selective and active HDAC I/IIb inhibitor, and the injectable formulation of PM (PMF) based on the compound prescription containing cyclodextrin completely can overcome PM's poor solubility and improves its
Externí odkaz:
https://doaj.org/article/0d7da28d05d149efa099f6bd699967a1
Autor:
Lindsey A. Murphy, Amanda C. Winters
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3248 (2023)
Acute myeloid leukemia (AML) is a rare subtype of acute leukemia in the pediatric and adolescent population but causes disproportionate morbidity and mortality in this age group. Standard chemotherapeutic regimens for AML have changed very little in
Externí odkaz:
https://doaj.org/article/8ea1843eaf054dd08613de185b4b329e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.